Send to

Choose Destination
Dermatol Clin. 2014 Apr;32(2):123-35. doi: 10.1016/j.det.2013.12.008.

What's new in objective assessment and treatment of facial hyperpigmentation?

Author information

Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, 5001 El Paso Dr, El Paso, TX 79905, USA. Electronic address:
College of Physicians and Surgeons, Columbia University Medical Center, 630 W 168th Street, New York, NY 10032, USA; Society Hill Dermatology, 932 Pine Street, Philadelphia, PA 19107, USA.
Department of Dermatology, University of Texas Southwestern Medical Center, 5939 Harry Hines Boulevard #300, Dallas, TX 75235, USA.


Facial hyperpigmentation is common and challenging to treat in darker-skinned populations. A Medline literature search of articles published up to October 2013 reporting the objective assessment of and/or treatment for melasma, postinflammatory hyperpigmentation, dermatosis papulosa nigra, lichen planus pigmentosus, and erythema dyschromicum perstans was reviewed. Objective assessment was only reported for melasma and postinflammatory hyperpigmentation. Furthermore, randomized controlled trial evidence was only reported for melasma. Although progress has been made, there is a need to develop more objective outcome measures and effective treatments for hyperpigmentation.


Dermatosis papulosa nigra; Erythema dyschromicum perstans; Lichen planus pigmentosus; Melasma; Objective assessment of pigmentation; Postinflammatory hyperpigmentation; Treatment

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center